课题基金 / 基金详情

Elucidating a role for Rho-kinase-thrombospondin signaling in experimental and human bronchopulmonary dysplasia: Novel targets for prevention and treatment of chronic lung disease in premature newborns.

Elucidating a role for Rho-kinase-thrombospondin signaling in experimental and human bronchopulmonary dysplasia: Novel targets for prevention and treatment of chronic lung disease in premature newborns.
阐明 Rho-激酶-血小板反应蛋白信号在实验性和人类支气管肺发育不良中的作用：预防和治疗早产儿慢性肺病的新目标。
批准号：
388735
负责人：
Jankov Robert P
金额：
$52.94万
依托单位：
Children's Hospital of Eastern Ontario- Ottawa Children's Treatment Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=388735&lang=en
关键词：
Animal Models Bronchopulmonary Dysplasia Histopathology Human Lung Tissue Nanoparticles Pulmonary Hypertension Rho-Kinase Thrombospondin Transforming Growth Factor Unbiased Stereology

项目摘要

项目成果

Jankov Robert P的其他基金

相似基金

相关文献

中文摘要
翻译
在加拿大，每年约有1500名婴儿极早产。在过去的20年里，医疗保健的进步提高了这些婴儿的存活率，但大约有一半是以严重的肺损伤为代价的，这种损伤称为支气管肺发育不良
英文摘要
About 1,500 babies are born extremely premature in Canada each year. Advances in medical care over the last 20 years have improved the survival of these babies, but in about half at the cost of a severe injury to the lung called bronchopulmonary dysplasia
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ceramides as a therapeutic target in experimental bronchopulmonary dysplasia
Sex differences in arginine function in experimental and human bronchopulmonary dysplasia
Preclinical Assessment of Rho-kinase Inhibitors for Chronic Pulmonary Hypertension
Hypercapnia as Therapy for Neonatal Pulmonary Hypertension
海外基金